{
    "clinical_study": {
        "@rank": "89055", 
        "arm_group": {
            "arm_group_label": "Cohort 1", 
            "arm_group_type": "Experimental", 
            "description": "aflibercept IV infusion for 1 hour followed by FOLFIRI IV infusion every 2 weeks"
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To assess the safety and pharmacokinetics preliminarily of the dose of intravenous (IV)\n      aflibercept used in western studies in combination with FOLFIRI (Irinotecan, 5-Fluorouracil,\n      and Leucovorin) given intravenously every 2 weeks in Chinese patients with solid tumors.\n\n      Secondary Objectives:\n\n        -  To make a preliminary assessment of antitumor effects of the combination of FOLFIRI\n           plus aflibercept in patients with measurable disease (RECIST 1.1).\n\n        -  To  evaluate the immunogenicity of IV aflibercept."
        }, 
        "brief_title": "A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasm Malignant", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Total duration of the study per patient is in the range of 17 to 29 weeks.\n\n      This trial is being conducted in China, where the INN designation for the study molecule is\n      \"aflibercept\" and this term is therefore used throughout the synopsis. In the US, the US\n      proper name is \"ziv-aflibercept\"."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        - Histologically or cytologically confirmed solid malignancy that is metastatic or\n        unresectable for which FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) treatment is\n        appropriate\n\n        Exclusion criteria:\n\n          -  Treatment with chemotherapy, hormonal therapy, radiotherapy, surgery, or an\n             investigational agent within 28 days\n\n          -  Eastern Cooperative Oncology Group (ECOG) >1\n\n          -  Need for a major surgical procedure or radiation therapy during the study\n\n          -  Diagnosis of squamous-cell lung cancer\n\n          -  Cumulative radiation therapy to > 25% of the total bone marrow\n\n          -  History of brain metastases\n\n          -  Inadequate organ and bone marrow function\n\n          -  Uncontrolled hypertension\n\n          -  Evidence of clinically significant bleeding diathesis or underlying coagulopathy\n\n          -  Prior FOLFIRI treatment but have not been appropriate for safety reasons\n\n          -  Patients with known Gilbert's syndrome\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930552", 
            "org_study_id": "TCD11470", 
            "secondary_id": "U1111-1115-7286"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "Pharmaceutical form:Solution for infusion Route of administration: Intravenous", 
                "intervention_name": "Aflibercept AVE0005", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 1", 
                "description": "Pharmaceutical form:Solution for infusion Route of administration: Intravenous", 
                "intervention_name": "Leucovorin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 1", 
                "description": "Pharmaceutical form:Solution for infusion Route of administration: Intravenous", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 1", 
                "description": "Pharmaceutical form:Solution for infusion Route of administration: Intravenous", 
                "intervention_name": "5-Fluorouracil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Irinotecan", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100071"
                    }, 
                    "name": "Investigational Site Number 156002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510060"
                    }, 
                    "name": "Investigational Site Number 156001"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Aflibercept in Combination With FOLFIRI Administrated Every 2 Weeks in Chinese Patients With Advanced Solid Malignancies", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of patients with standard safety assessments (adverse events and laboratory tests)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to last treatment + 30 days"
            }, 
            {
                "measure": "Pharmacokinetics:  Assessment of plasma concentrations of aflibercept, CPT-11 (irinotecan) and Fluorouracil (5-FU)", 
                "safety_issue": "No", 
                "time_frame": "Up to last aflibercept administration + 90 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930552"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Anti-tumor activity assessment - overall response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 17 Weeks"
            }, 
            {
                "measure": "Anti-tumor activity assessment - duration response", 
                "safety_issue": "No", 
                "time_frame": "Up to 17 Weeks"
            }, 
            {
                "measure": "Anti-aflibercept antibody detection", 
                "safety_issue": "Yes", 
                "time_frame": "Up to last aflibercept administration + 90 days"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}